Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Pfizer, Riding Tax Changes, Puts Up Huge 4Q Profit

By LINDA A. JOHNSON , AP Medical Writer | January 30, 2018

Pfizer company logo at the company’s headquarters in New York. Pfizer Inc. reported earnings Tuesday, Jan. 30, 2018. (Credit: AP Photo/Richard Drew)

Pfizer’s fourth-quarter profit soared to $12.27 billion thanks to a huge tax benefit related to the U.S. tax system overhaul.

The biggest U.S. drugmaker on Tuesday reported an $11.34 billion benefit, mainly from recalculating deferred tax liabilities. Pfizer also said it will take a charge of approximately $15 billion, payable to the Treasury over eight years, to cover taxes on profits held overseas that it plans to bring back to the U.S.

The New York company said those figures may need to be adjusted and did not disclose how much money it will “repatriate.”

But it issued a forecast for adjusted 2018 earnings in the range of $2.90 to $3 per share, higher than in the past couple years, with revenue in the range of $53.5 billion to $55.5 billion.

The maker of Viagra and pain medicine Lyrica said its net income for the fourth quarter amounted to $2.02. A year earlier, Pfizer posted net income of $775 million, or 13 cents per share.

Adjusted for non-recurring gains and discontinued operations, Pfizer’s fourth-quarter earnings amounted to $3.77 billion, or 62 cents per share. That’s 6 cents better than analysts polled by Zacks Investment Research had projected.

Pfizer posted revenue of $13.7 billion in the period, up 1 percent from a year ago and also surpassing Wall Street expectations of $13.61 billion.

Sales growth was led by Lyrica, the Prevnar 13 pneumococcal vaccine and several newer medicines, including clot-preventer Eliquis, breast cancer drug Ibrance and rheumatoid arthritis pill Xeljanz.

In premarket trading Tuesday, shares of Pfizer Inc. fell 62 cents, or 1.6 percent at $38.40.
__________________________________________________________

Elements of this story were generated by Automated Insights using data from Zacks Investment Research.

(Source: Associated Press)


Filed Under: Drug Discovery

 

Related Articles Read More >

Lokavant’s Spectrum v15 uses AI to cut trial-feasibility modeling from weeks to minutes
Prime time for peptide-based drug discovery 
Why smaller, simpler molecular glues are gaining attention in drug discovery
Glass vial, pipette and woman scientist in laboratory for medical study, research or experiment. Test tube, dropper and professional female person with chemical liquid for pharmaceutical innovation
Unlocking ‘bench-to-bedside’ discoveries requires better data sharing and collaboration
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE